TCRX

Tscan Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 0/10
Tscan Therapeutics sales and earnings growth
TCRX Growth
Neutral
  • Revenue Y/Y↑ 105.52%
  • EPS Y/Y↑ 11.93%
  • FCF Y/Y↓ -0.94%
Tscan Therapeutics gross and profit margin trends
TCRX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1360.60%
  • ROIC 5Y↓ -59.53%
Tscan Therapeutics net debt vs free cash flow
TCRX Risk
Great
  • Debt / Equity↓ 1.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -43.7

Tscan Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks